PRZOOM - /newswire/ -
London, United Kingdom, 2009/08/12 - New analysis from Frost & Sullivan, World Pharmacovigilance Markets in Lifesciences, finds that the world pharmacovigilance market was worth $1859.9 million in 2007 and is estimated to reach $2252.2 million in 2015.
The challenge to manage adverse events in an optimal and efficient way and, at the same time, adhere to regulatory requirements has dictated the need for cutting edge pharmacovigilance tools and technologies.
New analysis from Frost & Sullivan (healthcareIT.frost.com), World Pharmacovigilance Markets in Lifesciences, finds that the world pharmacovigilance market was worth $1859.9 million in 2007 and is estimated to reach $2252.2 million in 2015. In this study, Frost & Sullivan's expert analysts thoroughly examine the following technologies: drug safety database systems and signal detection systems.
"Regulatory bodies such as the Food & Drug Administration (FDA) and European Medicines Agency (EMEA) are intensifying safety regulations, thereby boosting the adoption rates of pharmacovigilance systems by pharmaceutical companies," notes Frost & Sullivan Senior Analyst E.Sujith. "The need to operate in a cost-effective way is inducing pharmaceutical companies to outsource/offshore their pharmacovigilance operations."
For large companies, the volume of adverse events is sizeable. Even a product from a mid-size company can generate a high volume of adverse events. There is significant potential for outsourcing/offhsoring for mid-sized companies as well.
Most top pharmaceutical companies have well-established systems and processes. Consequently, they are not willing to replace these systems as this entails high costs and is also time consuming.
Moreover, the migration of data from one system to another tends to be expensive for most companies. Aligning existing processes to fit in the new system is difficult.
Vendors should educate pharmaceutical companies about technology implications and its importance in their day-to-day operations. This will be necessary to overcoming prevailing skepticism about a new technology and its merits. They should conduct seminars and conferences to trigger interest and make pharmaceutical companies understand that technology that functions optimally can offer substantial return on investments.
"There will be advances in data integration that will support more flexible decision making on drug safety issues," remarks Sujith. "There is significant scope to extend pharmacovigilance systems to boost their integration with a range of other data sources such as medical records and clinical data."
If you are interested in a virtual brochure, which provides a brief synopsis of the research and a table of contents, then send an email to Katja Feick, Corporate Communications, at katja.feick[.]frost.com, with your full name, company name, title, telephone number, company email address, company website, city, state and country. Upon receipt of the above information, a brochure will be sent to you by email.
World Pharmacovigilance Markets in Lifesciences is part of the Healthcare & Life Sciences IT Growth Partnership Service program, which also includes research in the following markets: CRM Solutions Markets in Life Sciences, Imaging Solutions in Life Sciences Markets. All research included in subscriptions provide detailed market opportunities and industry trends that have been evaluated following extensive interviews with market participants.
Frost & Sullivan, the Growth Partnership Company, enables clients to accelerate growth and achieve best in class positions in growth, innovation and leadership. The company's Growth Partnership Service provides the CEO and the CEO's Growth Team with disciplined research and best practice models to drive the generation, evaluation and implementation of powerful growth strategies. Frost & Sullivan leverages over 45 years of experience in partnering with Global 1000 companies, emerging businesses and the investment community from more than 35 offices on six continents.
World Pharmacovigilance Markets in Lifesciences / M3A2